1	The spread of a validated molecular marker of artemisinin partial resistance pfkelch13
2	R622I and association with <i>pfhrp2/3</i> deletions in Eritrea
3	Selam Mihreteab ¹ , Karen Anderson ^{2,3} , Irene Molina - de la Fuente ^{4,5} , Colin J. Sutherland ⁶ ,
4	David Smith ^{2,3} , Jane Cunningham ⁷ , Khalid B Beshir ^{6*} , Qin Cheng ^{2,3*}
5	
6	¹ National Malaria Control Program, Ministry of Health, Asmara, Eritrea; ² Drug Resistance
7	and Diagnostics, Australian Defence Force Malaria and Infectious Disease Institute, Brisbane,
8	Australia; ³ QIMR-Berghofer Medical Research Institute, Brisbane, Australia; ⁴ Carlos III
9	Institute of Health, Madrid, Spain; ⁵ University of Alcala, Madrid, Spain; ⁶ Faculty of Infectious
10	Diseases, London School of Hygiene & Tropical Medicine, UK; ⁷ Global Malaria Programme,
11	World Health Organization, Geneva, Switzerland.
12	*Corresponding authors
13	Dr Qin Cheng, Australian Defence Force Malaria and Infectious Disease Institute, Weary
14	Dunlop Drive, Gallipoli Barracks, Enoggera, QLD 4051, Australia. email:
15	gin.cheng@defence.gov.au.
16	Dr Khalid B Beshir, Faculty of Infectious Diseases, London School of Hygiene & Tropical
17	Medicine, UK. Email: <u>Khalid.Beshir@lshtm.ac.uk</u> .
18	

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 ABSTRACT

21 Eritrea is the first African country to switch away from exclusive use of HRP2-based RDTs for the detection of *P. falciparum* due to high prevalence of *pfhrp2/3*-deleted *P. falciparum* 22 parasites causing false-negative RDT results. While heavy reliance on malaria RDTs played a 23 significant role in the rapid expansion of pfhrp2/3-deleted parasites in Eritrea, we 24 hypothesize that the use of antimalarial (artesunate-amodiaquine) may have also 25 26 contributed to their spread. We conducted a retrospective investigation of mutations in the 27 propeller domain of the *P. falciparum kelch13* gene in samples collected in 2016 (n=50) from 28 the Northern Red Sea Zone before the RDT switch away from HRP2-RDTs and in samples collected in 2018-2020 (n=587) from the Gash Barka, Anseba and Debub Zones after the 29 30 RDT switch. No mutations were identified in the 2016 samples. However, in 2018-2019 samples, we detected five different single non-synonymous mutations. The most prevalent 31 32 mutation was *pfk13* R622I, which was detected in samples collected from all health centres, 33 with an overall prevalence of 11.9% (ranging from 5.9% to 28%). Parasites carrying the R622I mutation have diverse microsatellite marker haplotypes, indicating that they had 34 35 evolved multiple times from different genetic backgrounds. The prevalence pfk13 R622I was significantly higher in single *pfhrp3*-deleted parasites (18.0%) compared to parasites without 36 37 pfhrp2/3 deletions (6.2%) and dual pfhrp2/3-deleted parasites (9.0%), suggesting association between the pfk13 R622I mutation and the pfhrp2/3 deletions in Eritrea. 38 Continuous monitoring the trends in *pfhrp2/3* and *pfk13* mutants is needed to inform 39 effective malaria management strategies in Eritrea. 40 41

Keywords. *P. falciparum*; RDTs; *pfhrp2* and *pfhrp3* deletions; HRP2; artemisinin
combination therapies (ACTs); artemisinin resistance; *P. falciparum Kelch13* gene.

2

44 BACKGROUND

Eritrea, located in the Horn of Africa, experiences low and seasonal transmission of both P. 45 falciparum and P. vivax malaria¹. In 2012, the Eritrean National Malaria Control Programme 46 47 (NMCP) successfully implemented a range of malaria interventions, including integrated vector control, the introduction of quality malaria RDT, and the deployment of artemisinin 48 combination therapy (ACT)². However, between 2015- 2020, malaria incidence and 49 mortality rates increased by more than 40%¹. This resurgence can be attributed, in part, to 50 the emergence of mutant parasites capable of evading diagnostic tests and the 51 development of partial resistance to artemisinin drugs among the parasites³. 52 In 2006, Eritrea introduced a HRP2-based combo RDT as a diagnostic tool for case malaria 53 management. However, within the span of a decade, the country reported a high 54 55 prevalence (62.0%) of *P. falciparum* parasites carrying *pfhrp2/3* gene deletions causing high rates of false negative HRP2-RDT results among symptomatic patients^{4,5}, making Eritrea one 56 of the countries severely impacted by these *pfhrp2/3*-deleted parasites. As a result, in 2016, 57

58 Eritrea switched from HRP2-based RDTs to non-HRP2-based alternatives⁶. In 2019,

approximately 2.5 years after the RDT switch, while the prevalence of parasites with gene

60 deletions remains high the prevalence of parasites with dual *pfhrp2/3* deletions, a primary

61 contributor to false negative RDT results, was much lower at multiple survey sites compared

62 to that at the original sites⁶.

63 In 2007, following the introduction of RDTs, the Eritrean NMCP made a decision to switch

64 the first line treatment of uncomplicated *P. falciparum* malaria from chloroquine and

65 sulphadoxine/pyrimethamine (CQ-SP) to the ACT artesunate-amodiaquine (AS-AQ) due to a

high treatment failure rate associated with CQ-SP⁷. To monitor the efficacy of AS-AQ, as

67 recommended by WHO, therapeutic efficacy studies (TES) have been conducted within the

68 country. These studies, conducted at various sentinel sites, have consistently demonstrated

that AS-AQ exhibited efficacy rates exceeding 90% on day 28 in all sites⁸⁻¹⁰, however, the

patient Day-3 parasite positive rate has increased between 2016 and 2019¹⁰.

In addition to TES, surveillance was undertaken to monitor molecular markers associated
with partial artemisinin resistance, point mutations in *P. falciparum kelch13* gene (*pfk13*), as

well as resistance to CQ (mutations in *pfcrt*) and AQ (mutations in *pfcrt* and *pfmdr1*). These 73 surveillance activities were conducted in the Gash Barka, Medefera and Debub Zones 74 between 2013-2014^{11,12} and in Gash Barka and Northern Red Sea Zones between 2016-75 76 2019¹⁰. The findings from these surveillance efforts supported the TES results. While high prevalence of AQ resistance-associated alleles of pfcrt (CVIET haplotype) and pfmdr1 (Y184F 77 and N86Y) were continuously detected, prevalence of pfk13 mutations was low in 2013-78 79 2014, with a single R622I and T535M detected among 119 samples from Gash Barka, as determined through deep amplicon sequencing. However, a recent report showed that the 80 81 prevalence of pfk13 R622I mutation in isolates before treatment reached 8.6% in 2016 and 82 increased to 21.0% in 2019¹⁰.

83 The *pfk13* R622I mutation was first reported in a single sample collected from Zambia during 84 the years 2012-2014, as part of a broader study on the global distribution of *pfk13* mutations¹³. Subsequently, it was reported in two individual samples collected from 85 Mozambique and Somalia¹⁴. In Northern Ethiopia, specifically in a town close to the border 86 with Sudan, the prevalence of R622I was found to be 2.4% (3/25) in samples collected 87 during 2013-2014¹⁵. This prevalence increased to 9.3% (8/86) in samples collected between 88 2017 and 2018, indicating an expansion of the mutant in the area¹⁶. The R622I mutation has 89 90 been shown to possibly affect the function of *pfk13* by molecular modelling¹⁵, and it has recently been reported to associate with higher risk of day-3 positivity and recrudescence 91 following ACT treatment in Eritrea TES¹⁰. In gene-edited parasites, the R622I mutation 92 confers low levels of resistance to artemisinin in vitro¹⁰. 93

While existing data suggest that the major driving force behind the high prevalence of 94 pfhrp2/3 deletions in Eritrea was likely due to the use of HRP2-based RDTs ⁶, it is important 95 96 to consider that several other factors might also contribute to the rapid increase of the parasites in the country. Theoretically, various mechanisms such as fitness gains, the 97 98 development of drug resistance, and the absence of host immunity could all confer selective 99 advantages to *pfhrp2/3*-deleted parasites when facing competition or encountering 100 pressures from drug and immune system from the host. Conversely, the evasion of detection by RDTs due to *pfhrp2/3* deletions could also contribute to the survival and spread 101 102 of drug resistant parasites. Consequently, *pfhrp2/3*-deleted parasites could spread in communities by hitch-hiking alongside the spread of drug-resistant parasites or a newly 103

104 emerging strains for which there is no pre-existing immunity in the community¹⁷.

105 Conversely, drug resistant parasites might be similarly spread by hitch-hiking on the spread

106 of *pfhrp2/3*- deleted parasites. The interplay between *pfhrp2/3*-deleted parasites and drug-

- 107 resistant parasites is not clear, with both phenomena potentially influencing each other's
- 108 spread and survival within communities.

109 In this study, we conducted a retrospective analysis *pfk13* mutations using existing samples

- 110 collected from symptomatic patients seeking care more than 10 health facilities across 3
- 111 Zones as part of previous studies. These samples were originally collected during three
- separate periods: during 2016 survey and the 2019-2020 survey, both surveys aimed at
- assessing prevalence of *pfhrp2/3* deletions; and during the 2018-2019 severe malaria study.
- 114 Our primary objective was to investigate the prevalence of *pfk13* mutations in Eritrea and
- explore their potential relationship with *pfhrp2/3* deletions. The study contributes valuable
- insights into the potential selective forces the influence the relative abundance of diagnostic
- and drug-resistant parasites in the Eritrean context.

118 **METHODS**

119 Source and number of samples

120 In this retrospective study, patient samples were collected from two different studies:

121 1) Surveillance of pfhrp2/3 deletions: This study incorporated samples obtained from two cross-sectional surveys designed to investigate the prevalence of pfhrp2/3 deletion 122 among symptomatic patients (referred to as "survey samples"). The first survey was 123 conducted in 2016 at two hospitals in the Red Sea Zone, namely Ghindae and Massawa⁴, 124 from which 50 samples were obtained. A follow up pfhrp2/3 deletion survey took place 125 during 2019-2020, encompassing nine hospitals/Health Centres spanning three zones: 126 Gash Baka (Agordat, Shambuko, Tesseney, Tekobmia and Barentu), Anseba (Keren and 127 128 Hagaz) and Debub (Mendefera and Maimine)⁶. This boarder survey collected 714 P. 129 falciparum samples, with 417 (representing 66.0%) of these samples were used in the present study. 130

- 131 2) The severe malaria study. The study was conducted during the period of 2018-2019 with
- the aim of investigating the impact of *pfhrp2/3* deletions on clinical outcomes in Eritrea.
- 133 A total of 116 *P. falciparum* infected blood samples (referred to as "severe malaria
- 134 samples") were collected from three distinct zones: Gash Barka (Agordat and Barentu),
- 135 Anseba (Keren) and Debub (Menderfera, Emni-Haily, Areza, Dubarwa, and Mulki).
- 136 For data analysis, survey and severe malaria samples, collected between 2018 and 2020,
- 137 were merged according to health facilities where they were collected. In cases where
- less than five samples were obtained from each of the four health facilities in the Debub
- zone (Areza, Dubarwa, Emni-Haily and Mulki), these were consolidated into a single
- 140 group (A/D/E/M). The collection sites can be visualised on the map provided Figure 1.



- 141
- 142 Figure 1. Map of Eritrea showing locations of health facilities (red crosses) where
- samples were collected from (HP: hospital; HC: health centre).

144 Genomic DNA and Plasmodium infection

- 145 Genomic DNA extraction from survey samples had been previously described in earlier
- publications^{4,6}. Additionally, genomic DNA were isolated from severe malaria samples using
- 147 robotic system, following the same protocol as previously reported¹⁸.

148 Amplification and sequencing *pfk13*

- 149 For survey samples, which included 50 samples from the 2016, and 417 DNA samples
- randomly selected from different *pfhrp2/3* status groups of 2019-2020, the propeller region
- of the *pfk13* gene (codons 435 to 680) was amplified using published primers and
- 152 conditions¹⁹. Subsequently, amplified fragments were then sequenced from both ends by
- 153 Sanger sequencing using BigDye reagents.
- 154 For severe malaria samples, A 1033bp fragment, spanning from codon 380 to 724 of the
- 155 propeller region of *pfk13* amino acid sequences, was amplified using forward primer
- 156 (TAAGTGGAAGACATCATGTAACCAGAGA) and reverse primer
- 157 (GTCTAAAACCAGTGGAACAAAATCGT). Amplification of DNA was performed in a 25 μl
- reaction on thermal cycler (PCRmax, UK). The reaction mixture included 5 µl of extracted
- 159 genomic DNA, 200 nM of each primer, 3 mM of MgCl2, 300 μM of each dNTP (Meridian,
- 160 UK), 1X NH4 reaction buffer (Meridian, UK) and 1 U of the NEB High Fidelity Q5 polymerase.
- 161 The PCR conditions consisted of 95°C for 3 min, followed by 40 cycles of denaturation at
- 162 95°C for 30 sec, annealing at 55°C for 60 sec, and extension at 72°C for 2 min. The amplified
- 163 fragments were visualised using gel electrophoresis¹⁸. Subsequently, amplicon pooling and
- 164 cleaning were carried out as previously described²⁰. Library preparation and adaptor ligation
- 165 were carried out using the Oxford Nanopore native barcoding kit (sqk-nbd-112-96) in
- accordance with the manufacturer's protocol (Oxford Nanopore, UK).

167 Haplotype diversity and genetic relatedness.

168 A total of seven neutral microsatellite markers (TA1, PolyA, PfPK2, TA109, 2490, 313, and 169 383) were analysed as part of previous studies^{4,6}. Haplotype data were available for 184 170 survey samples, which were included in the current study - 50 from 2016 and 134 from 171 2019/2020. To assess the genetic diversity and genetic relatedness of parasite haplotypes 172 with different *pfk13* variants, we employed FSTAT and PHYLOViZ online software (version 173 1.1) using instructions provided by the developers.

pfhrp2 and pfhrp3 gene status 174

The status of *pfhrp2* and *pfhrp3* gene in all samples was evaluated using a multiplex qPCR 175 method. This method simultaneously amplifies a fragment of the *pfhrp2* and *pfhrp3* exon2, 176 177 pLDH and human tubulin gene ²¹. Published primer and probe sequences, as well as PCR 178 reagents and conditions, were used for assessing sever malaria samples. For survey samples, we introduced some modifications: quencher on the *pfhrp2* (BHQ1) and *pfldh* (BHQ2) 179 probes were adjusted, Quantinova multiplex PCR kit master mix (QIAGEN) was utilized, and 180 the Mic qPCR cycler (Bio Molecular Systems) was employed. In the classification of samples 181 as having a pfhrp2 and/or pfhrp3 deletion, a threshold was set at Δ Cq (Cq_{pfhrp2} - Cq_{pfldh} 182 and/or Cq_{pfhrp3} - Cq_{pldh} $\geq 3^{21}$. Samples exhibiting Cq_{pldh} values exceeding 35 cycles were 183 184 deemed indeterminate due to insufficient DNA for analysis.

Quantification of parasite density 185

To determine the quantity of parasite DNA ($pg/\mu L$) in survey samples, we relied on the Cq_{pldh} 186

187 value of each sample in comparison to a 3D7 standard curve. This standard curve was

188 generated using serial dilutions of 3D7 DNA at 1, 0.1, 0.01 and 0.001 ng/ μ L, and it was

included in each multiplex gPCR run. In case of the severe malaria samples, parasite density 189

- estimation was conducted against the WHO International Standard²², as previously 190
- described¹⁸. 191

192 **Ethics considerations**

The surveys of *pfhrp2/3* deletions were granted approval by the Eritrean MOH Research and 193

Ethical Committee. Laboratory analyses on collected samples received approval from the 194

Departments of Defence and Veterans Affairs Human Research Ethics Committee (DDVA 195

HREC 15-004). Additionally, the severe malaria study was granted approval by LSHTM Ethics 196

Review Committee (#11979). 197

198 Data analysis

- 199 Sequence analysis: Sequences of *Pfk13* from survey samples were aligned using
- MEGA7.0.26²³. SNPs were identified by comparing these alignments with *pfk13* sequence in 200
- 3D7 (PF3D7 1343700). For severe malaria samples, amplicon reads were analysed using the 201

python language and well-established bioinformatics tools as described previously, with
 some slight modifications²⁴. Sequencing alignment was performed using minimap2
 software²⁵. Mutation prevalence analysis was conducted using the R-package vcfR (version
 1.12.0) and plyr (version 1.8.6).

Statistical analysis: To compare mutation prevalence and proportions between sample
groups, chi-squired test and odds ratio (OR) analysis were employed. Additionally,
comparisons of median parasite DNA concentrations and parasite densities among sample
groups were carried out using Mann-Whitney test.

210

211 **RESULTS**

212 Prevalence of *pfk13* mutation

Sequence analysis of 50 samples collected in 2016 revealed a wild type *pfk13* gene in all 213 samples, indicating the absence of mutations. In contrast, analysis of sequences obtained 214 from the combined pool of 587 survey and severe malaria samples collected between 2018 215 and 2020) samples revealed five different non-synonymous mutations: E605K, R622I, 216 N657K, K658E and S679L. Importantly, each mutant *pfk13* sequence contain only a single 217 amino acid mutation within the propeller region, with no combinations observed. Among 218 219 these mutations, the R622I mutation had the highest overall prevalence of 11.9% (70/587). 220 Following this, N657K the N657K mutation was observed in 0.3% of the samples (2/471). Meanwhile, the E605K, K658E and S679L mutations were each detected in a single sample, 221 222 giving a 0.2% (1/587) prevalence (Supplemental Table 1).

223 Distribution of pfk13 mutations

The samples carrying the E605, K658E, S679L and N657K mutations were exclusively

225 collected from the Gash Barka zone. However, the R622I mutation was identified in samples

- collected from all health facilities in the three zones with a prevalence exceeding higher
- than 10% in eight of these health facilities (Figure 2, Supplemental Table 1). The prevalence
- of R622I was highest in Hagaz hospital (28.0%, 7/25) in the Anseba zone, while the lowest
- prevalence was observed in samples obtained from Mendefera Hospital (5.9%, 3/51) in the

- 230 Debub zone. The prevalence of R622I was significantly higher in Hagaz compared to
- 231 Mendefera (Chi-squared test, p=0.0078), Keren (9.9%, Chi-squared test p=0.0207) and
- Barentu (p=0.0341). However, no statistical differences were observed at the zone level
- 233 (p>0.05). The prevalence for R622I were 11.9% (44/370) in Gash Barka, 13.8% (16/116) in
- Anseba and 9.9% (10/101) in Debub zone (Figure 2, Supplemental Table 1).



235

Figure 2. Prevalence of K13 mutations among health facilities (years 2018 - 2020), zones
and overall. *p<0.05; **p <0.01.

238 Haplotype diversity and genetic relatedness of *pfk13* R622I mutants

To gain insight into whether the R622I mutants shared a common ancestry and to assess if 239 240 they were undergoing expansion, we analysed microsatellite haplotypes obtained from previous studies^{4,6}. We examined 184 survey samples, of which 26 carried the *pfk13* R622I 241 mutation. Among these 26 samples, we identified 23 unique haplotypes, with all but two 242 were found in one sample each. The remaining two haplotypes were shared between two 243 and three samples (Supplemental Table 2). In contrast, among the remaining 158 samples 244 with the wild-type 622R, we identified 87 unique alleles. The overall genetic diversity, 245 246 represented by H_E values, among R622I mutants was calculated at 0.4774 (95% CI: 0.1873 – 0.7676), which is slightly lower than that of the 622R wild-type parasites (0.5773, 95% CI: 247

- 248 0.3760 0.7786). However, these difference was not statistically significant (FSTAT,
- p=0.0500, determined after 20 permutations, Supplemental Table 3).
- 250 Our genetic relatedness analysis revealed that while 15 of the 23 R622I mutant haplotypes
- 251 were closely related within a cluster, the remaining eight mutant haplotypes were not
- closely related to each other, suggesting independent genetic origins (Figure 3). These
- 253 findings indicate parasites carrying R622I mutation had evolved from different genetic
- 254 backgrounds, involving both clonal expansion and independent emergence.



255

256 Figure 3. Genetic relatedness of parasites carrying the *pfk13* R622I mutation (in Pink) or

257 wild-type 622R (in Green): A cut-off of two was applied, meaning that only parasite

258 haplotypes with five or more identical alleles of the seven markers tested were linked

259 together.

260 **Parasite density and** *pfk13* **mutations**

To investigate whether the *pfk13* mutations had impact on parasite fitness, we analysed the

262 parasite densities estimated for the survey samples, and we found no significant difference

in median parasite DNA concentration between samples carrying the R622I mutation and

those with the wild-type 622R (25.15, 95%CI: 18.55 – 40.72 vs 23.71, 95%CI: 18.55 – 28.23,

- p=0.6771, Figure 4). Similarly, our analysis of severe malaria samples indicated comparable 265
- (p=0.9367) median parasite densities (4674, 95%CI: 419.0 11430 vs 4242, 95%CI: 2436 -266
- 267 5444 parasites/ μ L) between the two *pfk13* genotypes (Figure 4). These results suggest that
- 268 the presence of *pfk13* mutations did not lead to significant differences in parasite density.



269

Figure 4. Comparison of parasite density between pfk13 R622I mutant and wild-type 622R 270 parasites. A: Concentration of parasite DNA in survey samples estimated by qPCR against a 271 272 standard curve. B: Parasite densities in severe malaria samples estimated by qPCR against 273 an International standard. Horizontal and vertical bars represent median and inter-quartile range, respectively. 274

- Proportion of samples with *pfhrp2/3* deletions 275
- Of the total 587 samples collected between 2018 and 2020 with *pfk13* sequences, 578 had 276
- pfhrp2 and pfhrp3 status determined. Among these 17 samples (2.9%) displayed a single 277
- pfhrp2 deletion, 255 samples (44.1%) exhibited a single pfhrp3 deletion, 145 samples 278
- (25.1%) with double pfhrp2/3 deletion, and 161 samples (27.9%) showed no deletion in 279
- either *pfhrp2* or *pfhrp3* (Figure 5, Supplemental Table 4). The remaining nine samples could 280
- 281 not have their *pfhrp2/3* status determined due to insufficient DNA.





284 Association of pfk13 R622I mutation with pfhrp2/3 deletions

Table 1 provides a summary of *pfk13* mutations observed in samples with varying *pfhrp2/3* 285

status. Samples with single *pfhrp3* deletion, in addition to having four out of five *pfk13* 286

287 mutations, also showed a significantly higher prevalence of R622I mutation (18.0%, 46/255)

288 compared to samples without pfhrp2/3 deletions (6.2%, 10/161, OR =3.89, p = 0.0006), or

those with dual *pfhrp2/3* deletions (9.0%, 13/145, OR = 2.23, p=0.0183) (Table 1, 289

290 Supplemental Figure 1A).

282

Out of the 70 samples with R622I mutations, one sample (1.4%) was classified as having a 291 single pfhrp2 deletion, 46 samples (65.7%) showed single pfhrp3 deletion, 13 samples 292 (18.6%) had dual pfhrp2/3 deletion and 10 samples (14.3%) had no pfhrp2/3 deletions 293 294 (Supplemental Figure 1B). In the remaining 508 wild type 622R samples however, the 295 proportions of single *pfhrp2*, single *pfhrp3*, dual *pfhrp2/3* deletion and no deletions were: 3.1%, 41.1%, 26.0%, and 30.7% respectively (Supplemental Figure 1B). The proportion of 296 single *pfhrp3* deletion was significantly higher (p<0.0001), while the proportion of no 297 298 deletions (p= 0.0071) was significantly lower in the R622I mutant compared to 622R wild type (Supplemental Figure 1B). 299

Table 1. Number and percentage of *pfK13* mutations in samples with varying *pfhrp2* and *pfhrp3* gene status. P-value, confidence interval, CI;

	ufbund/2 status	No.	E605K		R622I			N657K		K658E		S679L		WT	
	<i>pjnrp2/3</i> status	seq.	n	%	n	%	p-value,[CI], OR	n	%	n	%	n	%	n	%
	Single <i>pfhrp2</i> del	17	0	0.0%	1	5.9%	0.322, [0.52-150], 3.51	0	0.0%	0	0.0%	0	0.0%	16	94.1%
	Single <i>pfhrp3</i> del	255	0	0.0%	46	18.0%		2	0.8%	1	0.4%	1	0.4%	205	80.4%
	Dual <i>pfhrp2/3</i> del	145	0	0.0%	13	9.0%	0.0183,[1.13-4.68], 2.23	0	0.0%	0	0.0%	0	0.0%	132	91.0%
	No deletion	161	1	0.6%	10	6.2%	0.0006,[1.59-7.61], 3.89	0	0.0%	0	0.0%	0	0.0%	150	93.2%
	Total	578	1	0.2%	70	12.1%		2	0.3%	1	0.2%	1	0.2%	503	87.0%

and Odds Ratio (OR) are single *pfhrp3* deletion compared to other genotypes.

302

303 **DISCUSSION**

This study reports the prevalence and trends of *pfk13* mutations in the *P. falciparum*

- population in Eritrea from 2016 to 2020. Additionally, the study explores any potential
- 306 association between these mutations and *pfhrp2/3* deletions. By analysing these factors, the
- 307 study aims to gain a better understanding of the underlying factors influencing the
- 308 prevalence of *pfK13* mutations and *pfhrp2/3* gene deletions.

In 2016, a decade after widespread use of HRP2-based RDTs and AS-AQ in Eritrea, 62% of 309 310 the patients were infected with parasites lacking both *pfhrp2* and *pfhrp3* genes, rendering them undetectable by HRP2-based RDTs⁴. Notably, no mutation was detected in the pfk13311 gene in these samples. Despite the relatively small sample size, the data suggest that the 312 pfk13 mutations were either absent or present as a minor variants below the detection 313 limit, indicating very low frequencies at the two study sites during the survey period. This 314 315 finding aligns with an earlier study conducted in 2013/14, which reported a low prevalence 316 (0.8%, 1/119) of the R622I mutation in samples collected in Agordat and Barentu in the Gash Barka Zone¹² despite difference in sample collection sites and sequencing technologies. 317 Nevertheless, a more recent study reported a much higher prevalence (8.2%) of R6221 318 mutation among 280 samples collected during the 2016 TES conducted in the Gash Barka 319 320 Zone. This suggests that the distribution of R622I mutation was highly geographically heterogeneous in Eritrea in 2016. 321

In 2018-2020, two years after discontinuing the use HRP2-based RDTs, pfk13 R622I 322 mutations were identified in samples from all health facilities across three zones in Eritrea. 323 The prevalence of this mutation ranged from 2.5% to 28% with a mean prevalence of 11.9%, 324 and more than three-quarters of health facilities reported a prevalence exceeding 10%. In 325 specific locations like Agordat and Barentu, the prevalence of R622I had reached 13.7% 326 (13/95) and 11.0% (10/91), respectively, which is significantly higher than five years 327 328 earlier¹². The prevalence and wide distribution of R622I mutation detected in this study combined with that reported recently from TES¹⁰ demonstrate the R622I mutation has 329 become highly prevalent throughout of Eritrea since 2017. Microsatellite genotyping results 330 revealed that the increase in R622I prevalence was due to a combination of clonal 331 expansion of the mutant parasites and multiple independent emergences from different 332

333 genetic backgrounds, suggesting a complex evolutionary dynamics similar to that reported 334 in Ethiopia²⁶. It is likely that these mutations locally evolved in Eritrea rather than spreading 335 from neighbouring countries such as Sudan and Ethiopia, as genetic analysis using the same 336 haplotype data indicated differences between Eritrean parasite lineages, both with and 337 without *pfhrp2/3* deletions, and those from Sudan and Ethiopia/ Djibouti²⁷.

Interestingly, our study found that the R622I mutation was significantly enriched in single 338 pfhrp3-deleted (pfhrp2 positive) parasites and was relatively more prevalent in pfhrp2/3-339 deleted parasites in Eritrea. This observation, which was also reported from TES results¹⁰ in 340 341 Eritrea, contrasts with the findings in Ethiopia, where R622I was more prevalent in parasites without pfhrp2/3 deletions²⁶. This difference may be related to the types of RDTs used in 342 these countries at the time of the survey. While both countries had high prevalence of 343 pfhrp2/3 deletions, Eritrea switched from HRP2-based RDTs to pLDH-based RDTs in 2016, 344 whereas Ethiopia continued to use HRP2-based RDTs. We hypothesise a two-step evolution: 345 an initial emergence of pfhrp2/3 deletions under HRP2-based RDT selection pressure, 346 followed by the multiple independent emergences of the pfk13 R622I mutation in gene-347 348 deleted parasites under ACT selection pressure. In Eritrea, it is likely that pfhrp2/3 deletion 349 occurred first, given its higher prevalence compared to R622I. However, the driving force for a close association between pfhrp3 deletion and pfk13 R622I, and between pfhrp2/3 350 deletion and *pfk13* R622I is not clear but may be related to fitness gains in parasites carrying 351 both *pfhrp3* deletion and *pfk13* R622I mutations. While the data suggest that the mutation 352 does not appear to be associated with parasite density in peripheral blood, it could 353 potentially alter other characteristics such as transmissibility. 354

The influence of *pfhrp2/3* deletions on parasite fitness in infected individuals remains uncertain. Previous studies using genomic data from genetic crosses indicated no fitness cost, which reduces heritability associated with these deletions in the mosquito and liver stages²⁸. However, contradictory in vitro results have demonstrated fitness costs²⁹, suggesting these may be confined to the blood stages of the life cycle. These findings underscore the need for a deeper understanding of the interplay between drug resistance, *pfhrp2/3* deletions and parasite fitness in the evolution of *P. falciparum*.

The emergence of *P. falciparum* with *pfhrp2/3* deletions and *pfk13* mutations presents a 362 dual-threat scenario, conferring resistance to some diagnostic measures and therapeutic 363 364 interventions. Indications of potential co-occurrence between pfhrp2/3 deletions and pfk13 365 mutations have been documented, notably in Ethiopia. The findings in this study have shed light on instances of co-occurring *pfk13* R622I and *pfhrp2/3* variants in Eritrea ²⁶. At present, 366 a well-established correlation between pfhrp2/3 deletions and pfk13 mutations, as well as 367 their collective impact on parasite fitness, remains unclear. In vitro experimentations have 368 indicated that the *pfk13* C580Y mutation entails modest fitness costs when accompanied by 369 multicopy pm2/3, while it remains fitness-neutral in the presence of single pm2/3 copies³⁰. 370 371 We hypothesise a comparable scenario of fitness cost interplay between pfk13 mutations 372 and *pfhrp2/3* deletions. Further studies are required to decipher the interaction between pfhrp2/3 deletions and pfk13 mutations. 373

This study has several notable strengths. Firstly, our study is the first to document the 374 presence of *pfk13* R622I in two administrative zones (Anseba and Debub) and ten sub-zones 375 376 in addition to zones and sub-zones reported previously (Mihreteab 2023). This observation 377 signifies the expansion of *pfk13* R622I in Eritrean territory. Secondly, it is imperative to highlight that two of the newly identified sub-zones, Tesseney (located in close proximity to 378 the Sudanese border) and Maimine (situated near the Ethiopian border), carry notable 379 regional significance, requiring concerted regional response. Finally, the study's strength is 380 underscored by the substantial sample size collected in 2019 compared to most recently 381 published ¹⁰ for the same year. This sample size allows greater power for analysis of 382 association between *pfhrp2/3* deletion and *pfk13* mutation. Overall, our study 383 independently confirms the emergence, progress augmentation overtime and geographical 384 385 expansion of *pfk13* R622I, along with *pfhrp2/3* deletions correlation within Eritrea context.

This study has certain limitations. Firstly, samples collected before 2016 and after RDT switch (2018-2020) were obtained from different health facilities and zones, limiting direct comparisons in the prevalence of *pfhrp2/3* deletions and *pfk13* mutations between the two time points. Secondly, sequencing of *pfk13* was conducted on a subset of samples collected between 2018 and 2020. However, as all samples from the severe malaria study and a representative subset of samples from the 2019 survey (including 66 – 88% of *pfhrp2/3*

deletion and 59% of no deletion samples) were sequenced, significant bias on the outcomes

is unlikely. The study by Mihreteab et al. during the same timeframe using samples from TES 393 reported comparable results, thereby confirming the validity of our own findings. 394 395 Furthermore, this study focused on mutations within the propeller domain of the pfk13, 396 excluding possible mutations outside of the propeller domain that may contribute to 397 artemisinin resistance and interaction with gene deletions. The R622I mutation has primarily been reported in the Horn of Africa region, where very 398 high *pfhrp2/3* deletion prevalence was previously reported^{4,6,27,31,32}. Eritrea and Sudan 399 introduced AS-AQ, while Ethiopia and Djibouti use AL as first line therapy for uncomplicated 400 P. falciparum malaria. Our study in Eritrea demonstrates the expansion of pfk13 R622I 401 mutations in the country, with the mutation being enriched in single pfhrp3-deleted 402 parasites. While the emergence of *pfk13* R622I is likely associated with increased ACT use 403 and reduced transmission, its interaction with pfhrp2/3 deletions remains unclear. Although 404 405 R622I has been established as a confirmed molecular marker of partial artemisinin resistance in Eritrea, additional research is necessary to ascertain its applicability as a 406 407 molecular marker in neighbouring regions, where P. falciparum strains with distinct genetic backgrounds are prevalent. Continued monitoring of the trends in *pfhrp2/3* deletions and 408 409 pfK13 R622I mutations in Eritrea and the Horn of Africa with and without HRP2-based RDT 410 uses will provide insight into the relationship between pfhrp2/3 deletions and pfK13 R6221

412 Notes

411

392

413 **Acknowledgement.** The authors would like to thank patients for their

mutations, essential for the success of future control and elimination efforts.

- 414 participation of the studies. We would also like to thank Kathleen Krupinski from the WHO
- 415 GIS Centre for Health for map production.

416 **Disclaimer.** The views expressed in this article are those of the authors and do not

417 necessarily reflect the official policy or position of the Australian Department of Defence,

- 418 nor the WHO, or the Ministry of Health, Eritrea.
- 419 **Financial support.** This laboratory work was supported by the US DoD Armed Forces
- 420 Health Surveillance Division, Global Emerging Infections Surveillance Branch (AFHSD/GEIS),
- 421 PROMIS ID P0111_22_AF and Wellcome's Institutional Strategic Support Fund to KBB
- 422 (204928/Z/16/Z) The funders had no role in study design, data collection and analysis,
- 423 decision to publish, or preparation of the manuscript.

424 **Potential conflicts of interests.** All authors: No reported conflicts.

425 Author Contributions. SM, KB, JC and QC designed the study. KA, IM, DLF and DS

426 conducted laboratory experiments, acquired data and performed initial data analysis. CS

427 contributed materials and data analysis. SM organised and managed field surveys, sample

428 collection and epidemiological analysis. KB and QC analysed data and drafted the

429 manuscript. All authors participated in manuscript review and revision, and approved the

430 final manuscript.

431 Author contact details

- 432 Selam Mihreteab: smuqubay@gmail.com
- 433 Karen Anderson: <u>karena015@gmail.com</u>
- 434 Irene Molina de la Fuente: <u>i.molina@edu.uah.es</u>
- 435 Colin J Sutherland: Colin.Sutherland@lshtm.ac.uk
- 436 David Smith: <u>david.smith77@defence.gov.au</u>
- 437 Jane Cunningham: <u>cunninghamj@who.int</u>

Khalid B Beshir: Khalid.Beshir@lshtm.ac.uk 438

- Qin Cheng: qin.cheng@defence.gov.au 439
- References 440
- 441 WHO. World malaria report 2021. Geneva. (2021). 1
- 2 442 Berhane, A. et al. Gains attained in malaria control coverage within settings earmarked for 443 pre-elimination: malaria indicator and prevalence surveys 2012, Eritrea. Malar J 14, 467, 444 doi:10.1186/s12936-015-0992-9
- 445 10.1186/s12936-015-0992-9 [pii] (2015).
- 446 3 WHO. in World Health Organization, Geneva, Switzerland Vol. 447 https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022 448 (2022).
- 449 4 Berhane, A. et al. Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea. Emerg Infect Dis 24, 462-470, 450 451 doi:10.3201/eid2403.171723 (2018).
- 5 452 Berhane, A. et al. Rapid diagnostic tests failing to detect Plasmodium falciparum infections in 453 Eritrea: an investigation of reported false negative RDT results. Malar J 16, 105, 454 doi:10.1186/s12936-017-1752-9 (2017).
- 455 6 Mihreteab, S. et al. Epidemiology of mutant Plasmodium falciparum parasites lacking 456 histidine-rich protein 2/3 genes in Eritrea 2 years after switching from HRP2-based RDTs. Sci 457 *Rep* **11**, 21082, doi:10.1038/s41598-021-00714-8 (2021).
- 458 7 Ghebremeskel, T. Therapeutic efficacy of sulfadoxine/pyrimethamine plus chloroquine and 459 artesunate plus amodiaquine for the treatment of uncomplicated falciparum malaria. J. 460 Eritrean Med. Assoc. , 2, 14–16. , doi:https://doi.org/10. 4314/jema.v2i1.52701 (2007).
- 461 8 Mihreteab, S. Therapeutic efficacy study on artesunate + Amodiaquine (AS + AQ) for the 462 treatment of uncomplicated Plasmodium falciparum (Pf) malaria in Eritrea. J. Eritrean Med. 463 Assoc, 1, 9–12. (2014).
- 9 Mohammed, A. O., Tewolde, S., Estifanos, D., Tekeste, Y. & Osman, M. H. Therapeutic 464 465 efficacy of artesunate - amiodaquine for treating uncomplicated falciparum malaria at 466 Ghindae Zonal Referral Hospital, Eritrea. Acta Trop 177, 94-96,
- doi:10.1016/j.actatropica.2017.10.004 (2018). 467
- 10 Mihreteab, S. et al. Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in 468 Eritrea. N Engl J Med 389, 1191-1202, doi:10.1056/NEJMoa2210956 (2023). 469
- 470 11 Menegon, M., Nurahmed, A. M., Talha, A. A., Nour, B. Y. & Severini, C. Molecular 471 surveillance of antimalarial drug resistance related genes in *Plasmodium falciparum* isolates 472 from Eritrea. Acta Trop 157, 158-161, doi:10.1016/j.actatropica.2016.02.007 (2016).
- 473 12 L'Episcopia, M. et al. Targeted deep amplicon sequencing of kelch 13 and cytochrome b in 474 Plasmodium falciparum isolates from an endemic African country using the Malaria 475 Resistance Surveillance (MaRS) protocol. Parasit Vectors 13, 137, doi:10.1186/s13071-020-476 4005-7 (2020).
- 477 13 Menard, D. et al. A Worldwide Map of Plasmodium falciparum K13-Propeller 478 Polymorphisms. N Engl J Med 374, 2453-2464, doi:10.1056/NEJMoa1513137 (2016).
- 479 14 Wang, X. et al. Molecular surveillance of Pfcrt and k13 propeller polymorphisms of imported 480 Plasmodium falciparum cases to Zhejiang Province, China between 2016 and 2018. Malar J 481 19, 59, doi:10.1186/s12936-020-3140-0 (2020).
- 482 15 Bayih, A. G. et al. A Unique Plasmodium falciparum K13 Gene Mutation in Northwest 483 Ethiopia. Am J Trop Med Hyg 94, 132-135, doi:10.4269/ajtmh.15-0477

- 484 ajtmh.15-0477 [pii] (2016).
- 485 Alemayehu, A. A. et al. Expansion of the Plasmodium falciparum Kelch 13 R622I mutation in 16 Northwest Ethiopia. Research Square, doi:https://doi.org/10.21203/rs.3.rs-171038/v1 486 487 (2021).
- 488 Valdivia, H. O. et al. Spatiotemporal dynamics of Plasmodium falciparum histidine-rich 17 489 protein 2 and 3 deletions in Peru. Sci Rep 12, 19845, doi:10.1038/s41598-022-23881-8 490 (2022).
- 491 Beshir, K. B. et al. Plasmodium falciparum parasites with histidine-rich protein 2 (pfhrp2) and 18 492 pfhrp3 gene deletions in two endemic regions of Kenya. Sci Rep 7, 14718, 493 doi:10.1038/s41598-017-15031-2
- 494 10.1038/s41598-017-15031-2 [pii] (2017).
- 495 Ariey, F. et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. 19 Nature 505, 50-55, doi:10.1038/nature12876 496
- 497 nature12876 [pii] (2014).
- 498 20 Olukosi, A. Y. et al. Baseline prevalence of molecular marker of sulfadoxine/pyrimethamine 499 resistance in Ebonyi and Osun states, Nigeria: amplicon deep sequencing of dhps-540. J 500 Antimicrob Chemother 78, 788-791, doi:10.1093/jac/dkad011 (2023).
- 501 21 Grignard, L. et al. A novel multiplex qPCR assay for detection of Plasmodium falciparum with 502 histidine-rich protein 2 and 3 (pfhrp2 and pfhrp3) deletions in polyclonal infections. EBioMedicine 55, 102757, doi:10.1016/j.ebiom.2020.102757 (2020). 503
- 504 22 Padley, D. J., Heath, A. B., Sutherland, C., Chiodini, P. L. & Baylis, S. A. Establishment of the 505 1st World Health Organization International Standard for Plasmodium falciparum DNA for 506 nucleic acid amplification technique (NAT)-based assays. Malar J 7, 139, doi:10.1186/1475-507 2875-7-139
- 508 1475-2875-7-139 [pii] (2008).
- 509 Kumar, S., Stecher, G. & Tamura, K. MEGA7: Molecular Evolutionary Genetics Analysis 23 510 Version 7.0 for Bigger Datasets. Mol Biol Evol 33, 1870-1874, doi:10.1093/molbev/msw054 511 (2016).
- 512 24 Nolder, D. et al. Failure of rapid diagnostic tests in Plasmodium falciparum malaria cases 513 among travelers to the UK and Ireland: Identification and characterisation of the parasites. 514 Int J Infect Dis 108, 137-144, doi:10.1016/j.ijid.2021.05.008 (2021).
- 515 Li, H. New strategies to improve minimap2 alignment accuracy. Bioinformatics 37, 4572-25 516 4574, doi:10.1093/bioinformatics/btab705 (2021).
- 517 26 Fola, A. A. et al. Clonal spread of Plasmodium falciparum candidate artemisinin partial 518 resistance Kelch13 622I 1 mutation and co-occurrence with pfhrp2/3 deletions in Ethiopia 519 medRxiv preprint doi: <u>https://doi.org/10.1101/2023.03.02.23286711</u> (2023).
- 520 Rogier, E. et al. Plasmodium falciparum pfhrp2 and pfhrp3 Gene Deletions and Relatedness 27 521 to Other Global Isolates, Djibouti, 2019-2020. Emerg Infect Dis 28, 2043-2050, 522 doi:10.3201/eid2810.220695 (2022).
- 523 Sepulveda, N. et al. Global analysis of Plasmodium falciparum histidine-rich protein-2 28 524 (pfhrp2) and pfhrp3 gene deletions using whole-genome sequencing data and meta-analysis. 525 Infect Genet Evol 62, 211-219, doi:10.1016/j.meegid.2018.04.039 (2018).
- 526 Nair, S., Li, X., Nkhoma, S. C. & Anderson, T. Fitness Costs of pfhrp2 and pfhrp3 Deletions 29 527 Underlying Diagnostic Evasion in Malaria Parasites. J Infect Dis 226, 1637-1645, 528 doi:10.1093/infdis/jiac240 (2022).
- 529 Mok, S. et al. Mapping the genomic landscape of multidrug resistance in Plasmodium 30 530 falciparum and its impact on parasite fitness. bioRxiv, doi:10.1101/2023.06.02.543338 531 (2023).

532 31 Feleke, S. M. et al. Plasmodium falciparum is evolving to escape malaria rapid diagnostic tests in Ethiopia. Nat Microbiol 6, 1289-1299, doi:10.1038/s41564-021-00962-4 (2021). 533 534 Menegon, M. et al. Identification of Plasmodium falciparum isolates lacking histidine-rich 32 protein 2 and 3 in Eritrea. Infect Genet Evol 55, 131-134, doi:10.1016/j.meegid.2017.09.004 535 536 (2017).

- 537
- 538

Figure legends 539

- Figure 1. Map of Eritrea showing health facilities where samples were collected. 540
- Figure 2. Prevalence of K13 mutations among health facilities, zones and overall. *p<0.05; 541 **p <0.01. 542
- **Figure 3.** Genetic relatedness of parasites carrying the pfk13 R622I mutation (in pink) or 543
- wild type 622R (in green). Cut-off of 2 was used, in that only parasite haplotypes with ≥ 5 544
- 545 identical alleles of the 7 markers tested were linked together.
- Figure 4. Comparison of parasite density between pfk13 R622I mutant and wild type 622R 546
- parasites. Left panel: Parasite densities in survey participants estimated by qPCR from DBS-547
- 548 derived DNA. Right panel: Parasite densities for participants from the severe malaria study,
- 549 as estimated from blood films. Horizontal and vertical bars show median density and inter-
- 550 quartile range.
- 551 **Figure 5**. Proportion of samples with and without *pfhrp2* and *pfhrp3* deletions.